Sort by
Refine Your Search
-
Listed
-
Country
-
Employer
- ;
- Karolinska Institutet
- RMIT University
- ; University of Surrey
- AcademicTransfer
- Amsterdam UMC
- Technical University of Munich
- University of Nottingham
- ; The University of Manchester
- ; University of Bradford
- ; University of Cambridge
- ; University of East Anglia
- Australian Rotary Health PhD Scholarships
- ETH Zurich
- Forschungszentrum Jülich
- Institut Lumière Matière ILM- UMR 5306 CNRS / Université Claude Bernard Lyon 1
- International PhD Programme (IPP) Mainz
- Karolinska Institutet, doctoral positions
- Leiden University
- Slovak University of Agriculture in Nitra
- Technical University of Denmark
- Trinity College Dublin
- University Medical Center Utrecht (UMC Utrecht)
- University Medical Centre Groningen (UMCG)
- University of Amsterdam
- University of Bergen
- University of Cambridge
- University of Copenhagen
- University of Nicosia Medical School
- 19 more »
- « less
-
Field
-
View All Vacancies Veterinary Medicine & Science Location: UK Other Closing Date: Wednesday 14 August 2024 Reference: MED2008 Project title: Development and application of recombinant antibodies
-
diagnosed with RA. The van Egmond lab investigates the activation of neutrophils by (auto-)antibodies, and demonstrated that particularly antibodies of the IgA isotype potently activate neutrophils, and
-
immunisation is widely used for the development of polyclonal antibodies (pAb) and hybridomas for monoclonal antibody (mAb) production. These antibodies then enter the immunoassay, diagnostic and therapeutic
-
. While inactivated vaccines have controlled past BTV outbreaks, vaccination only confers protection against the homologous BTV serotype, with 29 serotypes currently existing. Neutralising antibodies
-
Primary supervisor - Dr Amit Sachdeva Secondary supervisor - Prof Andy Cammidge Over the last decade, several antibody-based biotherapeutics have been developed for treatment of cancer
-
the use of neutralising antibodies. The approaches to study the host-pathogen interaction of PRRSV-1 in vitro and in vivo shall include the: Use of in vitro systems to demonstrate effect of infection on APC
-
Institut Lumière Matière ILM- UMR 5306 CNRS / Université Claude Bernard Lyon 1 | Villeurbanne, Rhone Alpes | France | 23 days ago
antibody-antigen binding events, serving as a proof of concept. Since the sensing mechanism of SAW devices relies primarily on mass-loading to detect binding events, resolution can be limited by the low mass
-
to actively manipulate single-domain antibodies ie. nanobodies, conferring antigen-nanobody binding control. Consequently, analytes can be captured in space and time for on-demand detection, supporting real
-
-NCDs by screening for antibody responses against >500,000 ID antigens from infections, microbiome and environment, and 2) to disentangle environmental and genetic factors affecting the transition from
-
single cell biology technologies as well as antibody engineering, high dimensional flow cytometry and functional assays to understand molecular mechanisms of various autoimmune diseases. The candidate will